Analysts/Institutional Investor Meet/Con. Call Updates

20th August 2026 IOLCP/CGC/2026 National Stock Exchange of India Ltd. BSE Limited, Exchange Plaza, Plot no. C/1, G Block, Pheroze Jeejeebhoy Tower, Bandra-Kurla Complex, Bandra (E), Dalal Street, Mumbai- 400 001 Mumbai - 400 051 Security Code: 524164 Security Symbol: IOLCP Subject: Transcript of Earnings Conference Call, post declaration of Financial Results Q1 FY27. Dear Sir, Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith the transcript of Earnings Conference Call organized by the Company on 13th August 2026 post declaration of financial results for the quarter ended 30th June 2026. You are requested to take the same on record. Thanking You, Yours faithfully, for IOL Chemicals and Pharmaceuticals Limited Abhay Raj Singh Sr. Vice President & Company Secretary “IOL Chemicals and Pharmaceuticals Limited Q1 FY27 Earnings Conference Call” August 13, 2026 MANAGEMENT: MR. PARDEEP KUMAR KHANNA – CHIEF FINANCIAL OFFICER – IOL CHEMICALS AND PHARMACEUTICALS LIMITED MR. ABHAY RAJ SINGH – SENIOR VICE PRESIDENT AND COMPANY SECRETARY – IOL CHEMICALS AND PHARMACEUTICALS LIMITED MR. KUSHAL KUMAR RANA – DIRECTOR WORKS – IOL CHEMICALS AND PHARMACEUTICALS LIMITED MR. RAKESH MAHAJAN – FINANCE ADVISOR AND STRATEGIC HEAD – IOL CHEMICALS AND PHARMACEUTICALS LIMITED MODERATOR: MS. PRACHI AMBRE – MUFG INVESTOR RELATIONS Page 1 of 15 IOL Chemicals and Pharmaceuticals Limited August 13, 2026 Moderator: Ladies and gentlemen, good day and welcome to IOL Chemicals and Pharmaceuticals Limited Q1 FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Ms. Prachi Ambre from MUFG Investor Relations. Thank you, and over to you, ma'am. Prachi Ambre: Thank you, Huda. Good afternoon, everyone, and welcome to IOL Chemicals and Pharmaceuticals Limited Q1 FY27 Earnings Conference Call. Today, on the call, we have Mr. Pardeep Kumar Khanna, Chief Financial Officer; Mr. Abhay Raj Singh, Senior Vice President and Company Secretary; Mr. Kushal Kumar Rana, Director Works; and Mr. Rakesh Mahajan, Finance Advisor and Strategic Head to provide insights on the company's operational and financial performance. Before we begin the call, I would like to give a short disclaimer. This call may contain some of the forward-looking statements which are completely based upon our beliefs and expectations as of today. The statements are not a guarantee of our future performance and involve unforeseen risks and uncertainties. With this, I would like to hand over the call to Abhay, sir for his opening remarks. Over to you, sir. Thank you. Abhay Raj Singh: Thank you so much, Prachi, for the introduction. Good afternoon, everyone, and welcome to the Q1 FY27 earnings call of IOL Chemicals and Pharmaceuticals Limited. Thank you for joining us today and for your continued trust and support. I hope you have had an opportunity to review our financial results and investor presentation, filed with the stock exchanges and also available on our websites. We have started FY27 on a strong note, with healthy demand across key products, improved capacity utilization, favorable product mix, and continued focus on operational efficiency. In the pharmaceutical division, we continue to make good progress in diversifying our API portfolio beyond ibuprofen, with healthy demand across key products including paracetamol, pantoprazole, metformin, fenofibrate, and clopidogrel, etcetera. Non-ibu products contributed 43% of pharmaceutical revenue in Q1 FY27 compared with 36% in Q1 FY26, with revenue growing 67% year-on-year basis, and emerging as a key driver of growth in our pharma business. Importantly, this performance also demonstrates the benefits of the initiatives that we have taken over the past few quarters to strengthen our manufacturing platform and diversifying our API product portfolio. While ibuprofen remains an important part of our portfolio, our strategic focus is increasingly on building IOL as a diversified and integrated API platform, with multiple products contributing to our growth. Our international business also strengthened during the quarter, with exports increasing to about 28.5% of revenue, while the NMPA approval for clopidogrel in China further expands our regulatory reach and market opportunities. Page 2 of 15 IOL Chemicals and Pharmaceuticals Limited August 13, 2026 This progress is particularly encouraging against the backdrop of continued geopolitical uncertainties, supply chain challenges, and inflationary pressure across select raw materials. Our chemical business also delivered a strong performance during the quarter, supported by improved realizations, efficient raw material procurement, higher exports, and operational efficiencies. Capacity's enhancement across key products lines further strengthened our integrated manufacturing platform and provide us with greater flexibility to cater to demand across key end-use industries. Going forward, our focus remains on scaling our API portfolio, improving capacity utilization, expanding our presence in international regulated markets, and driving operational efficiencies through our integrated and backward integrated manufacturing platform. Our objective is not merely to add capacities, but to build meaningful and sustainable positions across a diversified API portfolio. The manufacturing capabilities, process expertise, and backward integration that we have developed over the years provide us with a strong foundation to scale these businesses. With that, I would now request Mr. Pardeep Khanna, our CFO, to take you through the financial performance for Q1 FY27. Pardeep Kumar Khanna: Thank you, Mr. Abhay. Good afternoon, everyone. I will now take you through the financial performance of the company for the Q1 of financial year ‘27, following which we will open the floor for questions-and-answers. During quarter one of financial year ‘27, the company reported revenue from operations INR756 CR as compared to INR551 crores in quarter one of financial year ‘26, registering a year-on-year growth of 37 percentage. On the operating front, EBITDA stood at INR111 crores compared with INR69.5 crores in quarter one of financial year ‘26, representing a growth of 60.7 percentage. EBITDA margin improved to 14.6 percentage compared with 12.4 percentage in the corresponding quarter. Coming to the bottom line, PAT stood at INR64.5 crores compared with INR34 crores in quarter one of corresponding year, registering a growth of 89.9%. PAT margin consequently improved to 8.4 percentage compared with 6.1 percentage in quarter one of financial year ‘26. The improvement in profitability reflects the benefit of higher operating leverage, better capacity utilization, improved product mix, and continued focus on operational efficiencies. Our export contribution also increased to 28.5% of revenue compared with 24.4% in same quarter of last financial year, reflecting the continuous strengthening of our international business. From a segment perspective, both pharmaceuticals and chemicals contributed to overall performance supported by healthy demand, improved utilization, and operational efficiencies. Going forward, our focus will remain on sustaining the growth momentum through better capacity utilization, continued improvement in product mix, operating efficiencies, and prudent cost management. At the same time, we will continue to maintain a disciplined approach towards capital allocation and investments with a focus on projects offering attractive long-term returns. Page 3 of 15 IOL Chemicals and Pharmaceuticals Limit [Showing first 8,000 characters — download PDF for full document]